Male contraceptive compositions and methods of use
AssigneesDana-Farber Cancer Institute, Inc., Baylor College of Medicine
InventorsJames Elliott Bradner, Martin Matzuk, Jun Qi
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for effecting male contraception.
Claims26
A method of reducing or inhibiting spermatogenesis in a healthy fertile male subject, the method comprising administering an effective amount of a compound or a salt thereof that inhibits a bromodomain testis-specific protein (BRDT) to the male subject, wherein the compound is of Formula (I):
- wherein:
- X is N or CR5;
- R5 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- RB is H, alkyl, hydroxylalkyl, aminoalkyl, alkoxyalkyl, haloalkyl, hydroxy, alkoxy, or —COO—R3, wherein alkyl is optionally substituted with halogen or —OH;
- ring A is phenyl or thienyl;
- each RA is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with halogen, amino, or —OH;
- or any two RA together with the atoms to which each is attached, can form a fused aryl or heteroaryl group;
- R is alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- each of which is optionally substituted with halogen, alkyl, amino, —OH, or aryl;
- R1 is —(CH2)n-L, in which n is 0-3 and L is H, —COO—R3, —CO—R3, —CO—N(R3R4), —S(O)2—R3, —S(O)2—N(R3R4), N(R3R4), N(R4)C(O)R3, aryl optionally substituted with alkyl, halogen, amino, or —OH, or heteroaryl optionally substituted with alkyl, halogen, amino, or —OH;
- R2 is H, D (deuterium), halogen, or alkyl optionally substituted with halogen, amino, or —OH;
- each R3 is independently selected from the group consisting of:
- (i) H, aryl, or heteroaryl;
- (ii) heterocycloalkyl;
- (iii) —C1-C8 alkyl, —C2-C8 alkenyl or —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
- —C3-C12 cycloalkyl, substituted —C3-C12 cycloalkyl, —C3-C12 cycloalkenyl, or substituted —C3-C12 cycloalkenyl, each of which may be optionally substituted with halogen, alkyl, amino, —OH, or heterocyclyl;
- (iv) N═CR4R6;
- each R4 is independently H, alkyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with halogen, alkyl, amino, —B(OH)2, —SO2Na, or —OH;
- or R3 and R4 are taken together with the nitrogen atom to which they are attached to form a 4-10-membered ring;
- R6 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with halogen, alkyl, amino, —B(OH)2, —SO2Na, or —OH;
- or R4 and R6 are taken together with the carbon atom to which they are attached to form a 4-10-membered ring;
- m is 0, 1, 2, or 3;
- wherein the compound contains a fluorine or chlorine atom.
A method of reducing the rate of male fertility in a healthy fertile male subject, the method comprising administering an effective amount of a compound or a salt thereof that inhibits a BRDT to the male subject, wherein the compound is of Formula (I):
- wherein:
- X is N or CR5;
- R5 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- RB is H, alkyl, hydroxylalkyl, aminoalkyl, alkoxyalkyl, haloalkyl, hydroxy, alkoxy, or —COO—R3, wherein alkyl is optionally substituted with halogen or —OH;
- ring A is phenyl or thienyl;
- each RA is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with halogen, amino, or —OH;
- or any two RA together with the atoms to which each is attached, can form a fused aryl or heteroaryl group;
- R is alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- each of which is optionally substituted with halogen, alkyl, amino, —OH, or aryl;
- R1 is —(CH2)n-L, in which n is 0-3 and L is H, —COO—R3, —CO—R3, —CO—N(R3R4), —S(O)2—R3, —S(O)2—N(R3R4), N(R3R4), N(R4)C(O)R3, aryl optionally substituted with alkyl, halogen, amino, or —OH, or heteroaryl optionally substituted with alkyl, halogen, amino, or —OH;
- R2 is H, D (deuterium), halogen, or alkyl optionally substituted with halogen, amino, or —OH;
- each R3 is independently selected from the group consisting of:
- (i) H, aryl, or heteroaryl;
- (ii) heterocycloalkyl;
- (iii) —C1-C8 alkyl, —C2-C8 alkenyl or —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
- —C3-C12 cycloalkyl, substituted —C3-C12 cycloalkyl, —C3-C12 cycloalkenyl, or substituted —C3-C12 cycloalkenyl, each of which may be optionally substituted with halogen, alkyl, amino, —OH, or heterocyclyl;
- (iv) N═CR4R6;
- each R4 is independently H, alkyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with halogen, alkyl, amino, —B(OH)2, —SO2Na, or —OH;
- or R3 and R4 are taken together with the nitrogen atom to which they are attached to form a 4-10-membered ring;
- R6 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with halogen, alkyl, amino, —B(OH)2, —SO2Na, or —OH;
- or R4 and R6 are taken together with the carbon atom to which they are attached to form a 4-10-membered ring;
- m is 0, 1, 2, or 3;
- wherein the compound contains a fluorine or chlorine atom.
Dependencies are inferred from the claim text.